Zina Affas Besse

Zina Affas Besse currently serves as a Board Member at LimmaTech Biologics AG and Axena Health, with additional board involvement at Biolinq and Eyenuk, Inc. As the Deputy Head of Global Health Private Equity and AXA IM Prime Impact Fund Advisor at AXA Investment Managers, Zina Affas Besse oversees healthcare investments aimed at improving global health while generating financial returns. Zina Affas Besse is also a Managing Partner at Global Health Funds, which manages private investments in innovative healthcare companies. Previously, Zina Affas Besse held the role of Senior Advisor at Global Health Investment Corporation and served as Chief Business Officer at Novintum Bioscience Ltd. Zina Affas Besse, who earned a PhD in Pharmacy & Medicinal Chemistry from the University of Nottingham, has extensive experience in the healthcare investment sector and a focus on advancing medical therapies.